ERBB2 and breast carcinoma: The CECCY (Carvedilol for Prevention of Chemotherapy-Related Cardiotoxicity) trial was a randomized, double-blind, placebo-controlled study of the beta-blocker carvedilol to prevent anthracycline cardiotoxicity in 200 patients with HER2-negative breast cancer.25